Search - tctmd.com

Displaying 1 - 20 of 24

Sort: Relevancy | Date

Presentation ACC 2025

Dapagliflozin after Transcatheter Aortic Valve Implantation

Presenter: Sergio Raposeiras-Roubin

March 29, 2025

Presentation ACC 2024

Self-Expanding Versus Balloon-Expandable TAVR in Patients with Aortic Stenosis and Small Aortic Annuli

Presenter: Howard C. Herrmann

April 07, 2024

Presentation ACC 2023

Transcatheter vs Surgical Aortic Valve Replacement in Low RiskPatients: 3-Year Outcomes from the EvolutLow Risk Trial

Presenter: John K. Forrest

March 05, 2023

Presentation ACC 2022

Edoxaban Versus Dual Antiplatelet Therapy For Valve Thrombosis And Cerebral Thromboembolism After Transcatheter Aortic-valve Replacement: A Randomized ADAPT-TAVR Trial

Presenter: Duk-Woo Park

April 04, 2022

Presentation ACC 2022

5-Year Incidence, Outcomes and Predictors of Structural Valve Deterioration of Transcatheter and Surgical Aortic Bioprostheses: Insights from the CoreValve US Pivotal and SURTAVI Trials

Presenter: Michael J. Reardon

April 04, 2022

Presentation ACC 2019

Primary Results From the Evolut Low Risk Trial

Presenter: Michael J. Reardon

March 17, 2019

Presentation ACC 2019

PARTNER 3: Transcatheter or Surgical Aortic Valve Replacement in Low Risk Patients with Aortic Stenosis

Presenter: Martin B. Leon

March 17, 2019

Presentation ACC 2017

Cerebral Embolic Protection In Patients Undergoing Surgical Aortic Valve Replacement (SAVR)

Presenter: Michael Mack

March 20, 2017

Transcatheter Aortic Valve Replacement with a Self-Expanding Prosthesis or Surgical Aortic Valve Replacement in Intermediate-Risk Patients: First Results from the SURTAVI Clinical Trial

Presentation ACC 2017

First Results from the SURTAVI Clinical Trial

Presenter: Michael J. Reardon

March 17, 2017

Presentation ACC 2016

Transcatheter or Surgical Aortic Valve Replacement in Intermediate Risk Patients with Aortic Stenosis

Presenter: Craig R. Smith

April 03, 2016

Presentation ACC 2016

Relationship Between Procedure Volume and Outcome for Transcatheter Aortic Valve Replacement in U.S. Clinical Practice: Insights from the STS-ACC TVT Registry

Presenter: John D. Carroll

April 03, 2016

Presentation ACC 2016

3-Year Results From the CoreValve US Pivotal High Risk Randomized Trial Comparing Self-Expanding Transcatheter and Surgical Aortic Valves

Presenter: Michael Deeb

April 03, 2016

Presentation ACC 2016

SAPIEN 3 Transcatheter Aortic Valve Replacement Compared with Surgery in Intermediate-Risk Patients: A Propensity Score Analysis

Presenter: Vinod Thourani

April 01, 2016

Presentation ACC 2015

Five-Year Outcomes after Randomization to Transcatheter or Surgical Aortic Valve Replacement: Final Results of The PARTNER 1 Trial

Presenter: Michael J. Mack

March 15, 2015

Presentation ACC 2015

Clinical and Echocardiographic Outcomes at 30 Days with the SAPIEN 3 TAVR System in Inoperable, High-Risk and Intermediate-Risk AS Patients

Presenter: Susheel K. Kodali

March 15, 2015

Presentation ACC 2015

A Randomized Comparison of Self-expanding Transcatheter and Surgical Aortic Valve Replacement in Patients with Severe Aortic Stenosis Deemed at Increased Risk for Surgery 2-Year Outcomes

Presenter: Michael J. Reardon

March 15, 2015

Presentation ACC 2014

Transcatheter Aortic Valve Replacement in Bicuspid Aortic Valve Disease

Presenter: Darren Mylotte

March 30, 2014

Presentation ACC 2013

Three-Year Outcomes after Transcatheter or Surgical Aortic Valve Replacement in High-Risk Patients with Severe Aortic Stenosis

Presenter: Vinod H. Thourani

March 11, 2013

Presentation ACC 2013

The Repositionable Lotus Aortic Valve Replacement System: Six-Month Outcomes in the REPRISE I Feasibility Study

Presenter: Ian T. Meredith

March 11, 2013

Presentation ACC 2013

New Data from the PARTNER Non-Randomized Continued Access Registry: Outcomes After Transfemoral Transcatheter Aortic Valve Replacement

Presenter: William F. Fearon

March 11, 2013

Advertisement

Dapagliflozin after Transcatheter Aortic Valve Implantation

Self-Expanding Versus Balloon-Expandable TAVR in Patients with Aortic Stenosis and Small Aortic Annuli

Transcatheter vs Surgical Aortic Valve Replacement in Low RiskPatients: 3-Year Outcomes from the EvolutLow Risk Trial

Edoxaban Versus Dual Antiplatelet Therapy For Valve Thrombosis And Cerebral Thromboembolism After Transcatheter Aortic-valve Replacement: A Randomized ADAPT-TAVR Trial

5-Year Incidence, Outcomes and Predictors of Structural Valve Deterioration of Transcatheter and Surgical Aortic Bioprostheses: Insights from the CoreValve US Pivotal and SURTAVI Trials

Primary Results From the Evolut Low Risk Trial

PARTNER 3: Transcatheter or Surgical Aortic Valve Replacement in Low Risk Patients with Aortic Stenosis

Cerebral Embolic Protection In Patients Undergoing Surgical Aortic Valve Replacement (SAVR)

First Results from the SURTAVI Clinical Trial

Transcatheter or Surgical Aortic Valve Replacement in Intermediate Risk Patients with Aortic Stenosis

Relationship Between Procedure Volume and Outcome for Transcatheter Aortic Valve Replacement in U.S. Clinical Practice: Insights from the STS-ACC TVT Registry

3-Year Results From the CoreValve US Pivotal High Risk Randomized Trial Comparing Self-Expanding Transcatheter and Surgical Aortic Valves

SAPIEN 3 Transcatheter Aortic Valve Replacement Compared with Surgery in Intermediate-Risk Patients: A Propensity Score Analysis

Five-Year Outcomes after Randomization to Transcatheter or Surgical Aortic Valve Replacement: Final Results of The PARTNER 1 Trial

Clinical and Echocardiographic Outcomes at 30 Days with the SAPIEN 3 TAVR System in Inoperable, High-Risk and Intermediate-Risk AS Patients

A Randomized Comparison of Self-expanding Transcatheter and Surgical Aortic Valve Replacement in Patients with Severe Aortic Stenosis Deemed at Increased Risk for Surgery 2-Year Outcomes

Transcatheter Aortic Valve Replacement in Bicuspid Aortic Valve Disease

Three-Year Outcomes after Transcatheter or Surgical Aortic Valve Replacement in High-Risk Patients with Severe Aortic Stenosis

The Repositionable Lotus Aortic Valve Replacement System: Six-Month Outcomes in the REPRISE I Feasibility Study

New Data from the PARTNER Non-Randomized Continued Access Registry: Outcomes After Transfemoral Transcatheter Aortic Valve Replacement

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content